ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,127.79
      1.26%
      US Tech 100
      17,442.00
      2.14%
      Dow Jones
      38,675.68
      1.18%
      Brent Oil
      82.765
      0.00%
      Bitcoin
      63,045.96
      0.25%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Alzamend Neuro Inc (ALZN)

      7. Alzamend Neuro Inc (ALZN) News

      ALZN

      Alzamend Neuro (ALZN)

      Alzamend Neuro Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:ALZN
      DateTimeSourceHeadlineSymbolCompany
      03/07/20244:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
      02/02/20244:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
      01/05/20244:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
      12/15/20234:30PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALZNAlzamend Neuro Inc
      12/11/20238:00AMBusiness WireAlzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder PatientsNASDAQ:ALZNAlzamend Neuro Inc
      11/20/20238:00AMBusiness WireAlzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder PatientsNASDAQ:ALZNAlzamend Neuro Inc
      11/16/20234:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
      11/16/20238:00AMBusiness WireAlzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price RequirementNASDAQ:ALZNAlzamend Neuro Inc
      11/13/20238:00AMBusiness WireAlzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001NASDAQ:ALZNAlzamend Neuro Inc
      10/30/20234:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
      10/30/20238:00AMBusiness WireAlzamend Neuro Announces Reverse Stock SplitNASDAQ:ALZNAlzamend Neuro Inc
      10/23/20238:00AMBusiness WireAlzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001NASDAQ:ALZNAlzamend Neuro Inc
      10/02/20238:00AMBusiness WireAlzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsNASDAQ:ALZNAlzamend Neuro Inc
      09/29/20234:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
      09/26/20236:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALZNAlzamend Neuro Inc
      09/22/20234:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
      09/22/20238:00AMBusiness WireAlzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing RequirementNASDAQ:ALZNAlzamend Neuro Inc
      09/13/20235:09PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALZNAlzamend Neuro Inc
      09/08/20235:05PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ALZNAlzamend Neuro Inc
      09/08/20235:00PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
      09/01/20234:30PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ALZNAlzamend Neuro Inc
      08/30/20238:00AMBusiness WireAlzamend Neuro Submits IND Application for Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsNASDAQ:ALZNAlzamend Neuro Inc
      08/24/20234:30PMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ALZNAlzamend Neuro Inc
      08/16/20234:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
      08/11/202312:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ALZNAlzamend Neuro Inc
      08/10/20234:30PMEdgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ALZNAlzamend Neuro Inc
      08/07/20234:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
      08/02/20234:31PMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ALZNAlzamend Neuro Inc
      07/27/20234:56PMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ALZNAlzamend Neuro Inc
      06/22/20234:31PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ALZNAlzamend Neuro Inc
       Showing the most relevant articles for your search:NASDAQ:ALZN